These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

526 related items for PubMed ID: 11490527

  • 1. Renal ostodystrophy during the developing stage of maintenance dialysis in Transylvania. Early development of periarticular calcifications and beta 2 microglobulin amyloidosis in spite of a relatively good prevention of secondary hyperparathyroidism.
    Oprisiu R, Bolosiu H, Boca I, Theodoru C, Elefterescu R, Brazier M, el Esper I, Leflon P, Ledeme C, Fournier A, Heinze V.
    Ann Med Interne (Paris); 1998 Mar; 149(2):67-75. PubMed ID: 11490527
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V, Torregrosa V.
    Nefrologia; 2008 Nov; 28 Suppl 3():67-78. PubMed ID: 19018742
    [Abstract] [Full Text] [Related]

  • 4. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S, Oprisiu R, Benamar L, Said S, Tataru Albu A, Arsenescu I, el Esper N, Morinière P, Fournier A.
    Nephrologie; 2000 Nov; 21(8):413-24. PubMed ID: 11213385
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Renal osteodystrophy (2): its treatment in renal insufficiency before dialysis].
    Hottelart C, Bako G, Oprisiu R, Georgita A, Presne C, Sarraj A, Morinière P, el Esper N, Fournier A.
    Nephrologie; 2000 Nov; 21(6):275-82. PubMed ID: 11117106
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
    Mornière P, Maurouard C, Boudailliez B, Westeel PF, Achard JM, Boitte F, el Esper N, Compagnon M, Maurel G, Bouillon R.
    Nephron; 1992 Nov; 60(2):154-63. PubMed ID: 1552999
    [Abstract] [Full Text] [Related]

  • 10. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L, Daugaard H, Nielsen PK, Jensen LT, Egsmose C, Olgaard K.
    Nephron; 1996 Nov; 74(1):89-103. PubMed ID: 8883025
    [Abstract] [Full Text] [Related]

  • 11. [Ultrasonography methods in the diagnosis of renal osteodystrophy].
    Tomić-Brzac H, Pavlović D.
    Acta Med Croatica; 2004 Nov; 58(1):43-9. PubMed ID: 15125393
    [Abstract] [Full Text] [Related]

  • 12. [Vitamin D treatment and renal osteodystrophy: indications and modalities].
    Fournier A, Morinière P, Yverneau-Hardy P, Westeel PF, Mazouz H, el Esper N, Ghazali A, Boudailliez B.
    Nephrologie; 1995 Nov; 16(2):165-90. PubMed ID: 7753302
    [Abstract] [Full Text] [Related]

  • 13. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.
    Weinreich T, Ritz E, Passlick-Deetjen J.
    Perit Dial Int; 1996 Nov; 16(3):260-8. PubMed ID: 8761540
    [Abstract] [Full Text] [Related]

  • 14. [Hyperparathyroidism secondary to renal insufficiency. Physiopathology, clinicoradiological aspects and treatment].
    Ben Hamida F, Ghazali A, Boudzernidj M, Amar M, Morinière P, Westeel P, Fournier A.
    Ann Endocrinol (Paris); 1994 Nov; 55(5):147-58. PubMed ID: 7857079
    [Abstract] [Full Text] [Related]

  • 15. 1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.
    Fournier A, Morinière PH, Oprisiu R, Yverneau-Hardy P, Westeel PF, Mazouz H, el Esper N, Ghazali A, Boudailliez B.
    Nephron; 1995 Nov; 71(3):254-83. PubMed ID: 8569975
    [Abstract] [Full Text] [Related]

  • 16. [Relative depletion in native vitamin D: a potential risk factor in Algerian hemodialysis patients with radiological evidence of hyperparathyroidism and osteomalacia independent of calcitriolemia].
    Atik A, Ghazali A, Achard JM, Rida Z, Oprisiu R, Brazier M, Leflon P, Gueris J, Morinière P, Sari Z, Fournier A.
    Nephrologie; 1997 Nov; 18(2):47-52. PubMed ID: 9182233
    [Abstract] [Full Text] [Related]

  • 17. Prevention of osteitis fibrosa, aluminium bone disease and soft-tissue calcification in dialysis patients: a long-term comparison of moderate doses of oral calcium +/- Mg(OH)2 vs Al(OH)3 +/- 1 alpha OH vitamin D3.
    Morinière P, Boudailliez B, Hocine C, Belbrik S, Renaud H, Westeel PF, Solal MC, Fournier A.
    Nephrol Dial Transplant; 1989 Nov; 4(12):1045-53. PubMed ID: 2517325
    [Abstract] [Full Text] [Related]

  • 18. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis.
    Morinière P, Fournier A, Leflon A, Hervé M, Sebert JL, Grégoire I, Bataille P, Guéris J.
    Nephron; 1985 Nov; 39(4):309-15. PubMed ID: 3982576
    [Abstract] [Full Text] [Related]

  • 19. [Rheumatologic and radiologic symptoms of secondary hyperparathyroidism: retrospective long-term study of 175 chronic hemodialysis patients].
    Mayet WJ, Hermann E, Wandel E, Elsen A, Schadmand S, Klose KJ, Poralla T, Meyer zum Büschenfelde KH, Köhler H.
    Z Rheumatol; 1991 Nov; 50(5):313-9. PubMed ID: 1776368
    [Abstract] [Full Text] [Related]

  • 20. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F, Corradi B, Imbasciati E.
    Adv Perit Dial; 1996 Nov; 12():239-44. PubMed ID: 8865912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.